Adult Clinical Trial
— VancoDATABayesOfficial title:
Vancomycin Dose Adjustments Comparing Trough Levels to The AUC0-24h/MIC Method Using a Bayesian Approach in a Hospitalized Adult Population: A Pilot Study
NCT number | NCT04756895 |
Other study ID # | 2021-600 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 1, 2021 |
Est. completion date | August 6, 2021 |
Verified date | September 2021 |
Source | CR-CSSS Champlain-Charles-Le Moyne |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This pilot study is a prospective, randomized, controlled, open-label trial to assess the feasibility of a randomized controlled trial of sufficient quality that would assess the efficacy and safety of vancomycin adjustments according to Area under the curve/Minimal inhibitory concentration (AUC0-24h/MIC) calculated by the Bayesian approach rather than by a trough dosage. Randomization will be stratified according to infection severity. Approximately 60 subjects meeting all inclusion and no exclusion criteria will be randomized to have pharmacists perform vancomycin dose adjustments with AUC0-24h / MIC calculated by the Bayesian approach versus the trough dosage approach.
Status | Completed |
Enrollment | 45 |
Est. completion date | August 6, 2021 |
Est. primary completion date | August 6, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - At least 18 years of age; - Hospitalized patients - Suspected or confirmed infection; - Anticipated IV vancomycin treatment for 24 hours or more. Exclusion Criteria: - Patients with renal replacement therapy (peritoneal dialysis, continuous renal replacement therapy or hemodialysis); - Treatment of vancomycin in continuous infusion; |
Country | Name | City | State |
---|---|---|---|
Canada | Charles-Le Moyne Hospital | Greenfield Park | Quebec |
Lead Sponsor | Collaborator |
---|---|
CR-CSSS Champlain-Charles-Le Moyne |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Validation of The Research Protocol | Evaluation of adhesion rate to the sampling protocol of 80% or more and adhesion rate to software recommendations of 90% or more | Through study completion, an average of 2 weeks | |
Primary | Evaluation of Recruitment | Evaluation of consent rate of 30% or more and the number of patients recruited per month of 10 or more | Baseline | |
Secondary | The proportion of patients who reach a therapeutic level in the first 48 hours | Percentage of patients who reach a therapeutic level in the first 48 hours | At 48 hours after the first dose of vancomycin | |
Secondary | Time to reach the vancomycin target | Number of hours necessary to reach the vancomycin target. Number of hours will be classified in the following categories: 24-48 hours, 49-96 hours, 97 hours and above. | During the vancomycin treatment | |
Secondary | The number of adjustments required to reach the vancomycin target | Number of dose adjustments required to reach the vancomycin target | During the vancomycin treatment | |
Secondary | The number of vancomycin dosage level monitoring to reach the vancomycin target | The number of vancomycin dosage level monitoring to reach the vancomycin target | During the vancomycin treatment | |
Secondary | The proportion of vancomycin dosage level monitoring in the vancomycin target | Percentage of vancomycin dosage level monitoring in the vancomycin target | During the vancomycin treatment | |
Secondary | The difference between the AUC calculated by the Bayesian method and the trapezoid method | Difference in percentage of the vancomycin AUC calculated by the Bayesian method and the trapezoid method | During the vancomycin treatment | |
Secondary | The difference between the initial prescribed dose and the dose suggested by the Bayesian software. | Difference in percentage of the initial prescribed dose and the dose suggested by the Bayesian software. | Baseline | |
Secondary | Proportion of acute kidney injury | Percentage of acute kidney injury. | During the vancomycin treatment | |
Secondary | Average daily dose of vancomycin | Average of the daily dose of vancomycin calculated in mg per kg of total body weight | Through study completion, an average of 2 weeks | |
Secondary | Operational Impact | Evaluation of the impact on pharmacist's time required for monitoring vancomycin | Immediately after the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06320626 -
Pharmacokinetic-guided Dosing of Emicizumab
|
Phase 4 | |
Recruiting |
NCT05841667 -
Impact of CES1 Genotype on Remimazolam
|
||
Completed |
NCT06355817 -
Distraction Techniques in Periocular Anesthesia: Tapping vs Vibration
|
N/A | |
Not yet recruiting |
NCT01209481 -
Impact of Educational Group Intervention on the Consumption of Fruit and Vegetables
|
N/A | |
Terminated |
NCT01570465 -
Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
|
||
Completed |
NCT04169646 -
Prevention and Intervention of Neck Pain in Swiss Office-Workers
|
N/A | |
Not yet recruiting |
NCT01943565 -
Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study
|
Phase 4 | |
Completed |
NCT00519298 -
Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03541837 -
Erector Spinae Plane Block and Pain Management in Cardiac Surgery
|
N/A | |
Active, not recruiting |
NCT00809575 -
Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes
|
||
Completed |
NCT06383117 -
Understanding Effects of Calcium on the Gut-Bone Axis
|
N/A | |
Completed |
NCT05012046 -
Effect of 100% Orange Juice on Food Intake and Glycemic Response in Adults
|
N/A | |
Completed |
NCT05597969 -
The Effect of an Application-based Health Intervention (FoodCoach) on Food Purchases in Switzerland
|
N/A | |
Terminated |
NCT01817153 -
Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock.
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05123352 -
Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies
|
||
Not yet recruiting |
NCT03728114 -
Effects of RIC on Cognitive Function and Blood Oxygen Levels in Unacclimatized Adult at High Altitude
|
N/A | |
Completed |
NCT01162863 -
Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
|
N/A | |
Completed |
NCT05570435 -
Efficacy of Milk Product Supplemented With Bioactives in Lowering Post Meal Glucose Response
|
N/A | |
Recruiting |
NCT03713931 -
PUMA Implementation 2
|
||
Completed |
NCT04443231 -
Prospective Clinical Study of Retinal Microvascular Alteration After ICL Implantation
|